drugset / Trial / NCT00772447

China Registration Study in Patients With Skin Infections

NCT00772447

Phase 3 Completed 265 enrolled AstraZeneca
RandomizedParallel-groupSingle-blindTreatment

Summary

The objectives of this study is to evaluate the Safety and Efficacy of Intravenous Daptomycin (Cubicin®)Compared with that of Comparator (Vancomycin or Vancomycin Followed by Semi-synthetic Penicillin-cloxacillin) in the Treatment of Chinese Subjects with Complicated Bacterial Skin and Skin Structure Infection due to Gram-Positive Pathogens.

Timeline

Start
2008-09
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Daptomycin Other / unclassified 4 mg/kg Intravenous
Comparator Vancomycin Other / unclassified 1 g
Comparator Vancomycin Other / unclassified 2 g
Comparator cloxacillin Other / unclassified 1 g
Comparator cloxacillin Other / unclassified 2 g